Nyangone Ekome Toung Chalomie

Dr. Nyangone Ekome Toung Chalomie


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2020 in Biomedicines
Verified
Journal Article
Open access
PDF file
FBFleury Augustin Nsole Biteghe
Fleury Augustin Nsole Biteghe
NCNyangone Ekome Toung Chalomie
Nyangone Ekome Toung Chalomie
NMNeelakshi Mungra
Neelakshi Mungra
GVGuillaume Vignaux
Guillaume Vignaux
NGNan Gao
Nan Gao
Stefan Dr. Stefan BarthStefan Dr. Stefan Barth
Stefan Dr. Stefan Barth
Melanoma is the least common form of skin cancer and is associated with the highest mortality. Where melanoma is mostly unresponsive to conventional therapies (e.g., chemotherapy), BRAF inhibitor treatment has shown improved therapeutic outcomes. Photodynamic therapy (PDT) relies on a light-activated compound to produce death-inducing amounts of reactive oxygen species (ROS). Their capacity to selectively accumulate in tumor cells has been confirmed in melanoma treatment with some encouraging results. However, this treatment approach has not reached clinical fruition for melanoma due to major limitations associated with the development of resistance and subsequent side effects. These adverse effects might be bypassed by immunotherapy in the form of antibody–drug conjugates (ADCs) relying on the ability of monoclonal antibodies (mAbs) to target specific tumor-associated antigens (TAAs) and to be used as carriers to specifically deliver cytotoxic warheads into corresponding tumor cells. Of late, the continued refinement of ADC therapeutic efficacy has given rise to photoimmunotherapy (PIT) (a light-sensitive compound conjugated to mAbs), which by virtue of requiring light activation only exerts its toxic effect on light-irradiated cells. As such, this review aims to highlight the potential clinical benefits of various armed antibody-based immunotherapies, including PDT, as alternative approaches for the treatment of metastatic melanoma.

1 August 2022 in Clinical and Translational Oncology
Verified
Journal Article
Closed access
PDF file
TDTahir Bashir Dar
Tahir Bashir Dar
FBFleury Augustin Nsole Biteghe
Fleury Augustin Nsole Biteghe
RKRuchi Kakar
Ruchi Kakar
Eric Chekwube AniogoEric Chekwube Aniogo
Eric Chekwube Aniogo
ZMZaria Malindi
Zaria Malindi
JNJean Marc Ngome Ndong
Jean Marc Ngome Ndong